Ophthalmology, first.
Onclave Health is launching with a deliberately narrow formulary — the two compounded sterile preparations every retina and cataract practice in the country relies on.
Bevacizumab Intravitreal Injection
The workhorse anti-VEGF therapy in modern ophthalmology — used off-label for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Compounded intravitreal bevacizumab costs roughly $50–$70 per dose versus $1,500–$2,000 for branded alternatives, and accounts for the majority of intravitreal injections performed in the United States.
National supply has been brittle. In 2024 the largest US supplier of repackaged Avastin exited the market entirely after a single sterility observation, leaving retina practices with two to three weeks of inventory. Onclave is being built to serve this category as a durable second source.
- Dosage form
- Pre-filled intravitreal syringe
- Concentration
- 1.25 mg / 0.05 mL
- Route
- Intravitreal
- Channel
- Ophthalmology & retina practices
Intracameral Moxifloxacin Injection
Injected into the anterior chamber at the close of cataract surgery to prevent post-operative endophthalmitis — the prophylactic standard established by the ESCRS endophthalmitis study and now used in the majority of US cataract cases. A preservative-free, single-use, pre-filled syringe removes the dilution and draw-up steps the surgical team would otherwise perform at the back table.
It pairs naturally with bevacizumab — the same cataract and retina practices order both, often on the same purchase order. Producing them side by side lets Onclave become the default sterile-compounding partner for ophthalmology in the region, rather than another single-product vendor.
- Dosage form
- Pre-filled syringe
- Preservative
- None
- Route
- Intracameral
- Channel
- Cataract surgery (ASCs & HOPDs)